Transcenta
Transcenta is a Suzhou antibody company whose Claudin 18.2 antibody osemitamab (TST001) is being tested with nivolumab and chemotherapy as first-line treatment for stomach cancer.
Overview
Transcenta, listed in Hong Kong, develops antibodies with its own continuous-manufacturing platform. Osemitamab (TST001), a high-affinity Claudin 18.2 antibody with enhanced antibody-dependent cytotoxicity, has shown activity with nivolumab and chemotherapy in first-line gastric and gastro-oesophageal junction cancer and has orphan designations for gastric and pancreatic cancer. TST003 targets Gremlin1 in solid tumours and TST005 is a PD-L1 and TGF-beta bifunctional antibody.
Scorecard
All companies- phase 1/2 +2
- modalities +2
- registry trials +5
TST001 is a monoclonal antibody from Transcenta Therapeutics (Hangzhou) Co., Ltd., in registered phase 2 trials for metastatic cancer.
TST003 is a monoclonal antibody from Transcenta Therapeutics (Hangzhou) Co., Ltd., in registered phase 2 trials for colorectal cancer.